spacer
home > epc
PUBLICATIONS

European Pharmaceutical Contractor

 

Published quarterly, European Pharmaceutical Contractor (EPC) covers the essential contract research issues between pharma companies and their CRO partners. The title, which is integrated within International Clinical Trials (ICT) magazine, offers a strategic view of the drug development industry – giving its pharma, biotech and CRO readership expert insight and analysis on the sponsor-service provider landscape.

EPC focuses on key trends, concerns and developments in contract research operations across the drug development spectrum, from preclinical to post-marketing. It explores the shifting collaborative needs and practical implications for sponsors and their contract partners, with the emphasis on building and managing effective collaborations.

Prompted by the synergies between outsourcing and trial operations, EPC joined forces with sister brand ICT in late-2015, in a move that brings added value to both brands. With EPC now an inserted edition within ICT, industry practitioners across these complementary subject areas now have unrivalled access to a wealth of shared views and analyses.

 

For further information please contact:

Advertising
Nick Matthews

Editorial
Thanh Thanh Lam

We're also on Twitter! Follow us @EPCmagazine

The latest digital edition of EPC can be viewed here
 

Read our publications on the go in the Samedan app for iPhone and iPad. You can download issues for offline reading and our archives go as far back as 2008! Download for free on the App Store.


epc
 
 
Featured in this issue
Marketplace & Business: Translation Feature
Translation Tools

Lingua Franca


Translation technology has grown in conjunction with the increasing number of clinical trials carried out globally. Trevor Korb at Corporate Translations wonders how these new tools can aid pharma.

Interview
Q&A: Electronic Patient-Reported Outcomes

Digital Approach

John Sage
at iCardiac tells EPC about the increasing demand for ePRO technologies, which opens up significant growth opportunities for developers of such innovations.

  Legal & Regulatory
Clinical Evaluation

Conform to the Norm: Part 2


Continuing from EPC February, Terry Winchell at GCP Innovative Dynamics further elaborates on current regulations concerning clinical investigator disqualifications, and shares practical advice.

spacer



Published quarterly in
February, May,
August and November


 

Industry Events

Outsourcing in Clinical Trials UK & Ireland 2016

22-23 June 2016, London

Arena International are delighted to announce the 3rd Annual Outsourcing in Clinical Trials UK & Ireland event, hosted in London on the 22nd – 23rdJune 2016.
More info >>

 
News and Press Releases

PPD Ranked as a Top Business Technology Innovator

Pharmaceutical Product Development, LLC (PPD) today announced it has been named for the fifth time to the InformationWeek Elite 100, a list of the top business technology innovators in the United States.
More info >>

air transport logo

 

White Papers

The Flexible Factory Concept: A flexible bioprocessing platform to meet the changing needs of biomanufacturing

GE Healthcare Life Sciences

For the past several years, the biopharma industry has been buffeted by dynamic market conditions that are rapidly reshaping manufacturing requirements. These factors include: • The rise of small-market pharmaceuticals that do not require the production scale of the previous “blockbuster” drug model • Increased titers and process productivity that generate more bulk-product within a much smaller manufacturing footprint • The emergence of biosimilars and continued evolution of healthcare reform, which will increasingly pressure drug pricing and require greater cost discipline • Greater competition and shorter patent protection timelines, which will further ratchet up time-to-market pressures • Tighter capital markets that will create heightened scrutiny for all new investment projects
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement